Search Results 41-50 of 4117 for ���������������katalk:PC53���
LB-100 is a small molecule that in laboratory and animal studies has shown activity when used by itself or together with drugs approved to treat some types of ...
Related publications. Zhu P, Sieben CJ, Xu X, Harris PC, Lin X. Autophagy activators suppress cystogenesis in an autosomal dominant polycystic kidney disease ...
The investigators want to find out what effects, good and/or bad, CAMP has on patients and their metastatic castration-resistant prostate cancer. Participation ...
Hypothesis: Identification of vulnerable atherosclerotic plaques (with or without neovascularization) using carotid CEUS is an independent predictor of MACE ( ...
... 53,53, 291000008,HC WALKER FOLDING ADJUST/FIXED,84,84, 291000009,HC WALKER FOLDING WHEELED,121,121, 291000010,HC WALKER FOLDING WHEELED,121,121, 291000011 ...
A Study to Evaluate the Effectiveness, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Pediatric Patients with Developmental and/or Epileptic ...
Bioinformatics is part of a large community of experts in technology like next-generation sequencing, experts in computer science, that help us develop ...
About this study. This is a Phase 2, open-label, 2-part, multicenter study in subjects with MSS relapsed/refractory colorectal cancer.
This randomized phase II trial studies how well olaparib, cediranib maleate, and standard chemotherapy work in treating patients with small cell lung cancer.
This is a phase I study of PICN alone and in combination with carboplatin and consisting of 2 sequential parts. Part A will characterize the pharmacokinetic ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Thanks to generous benefactors, your gift today can have 5X the impact to advance AI innovation at Mayo Clinic.